Amir Weiss - 05 Mar 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Chief Accounting Officer
Signature: /s/ Dov Bergwerk as attorney-in-fact for Amir Weiss
Issuer symbol: TEVA
Transactions as of: 05 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 07 Mar 2025, 16:29:10 UTC
Previous filing: 06 Mar 2025
Next filing: 10 Nov 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+3,566	+13%		30,250	05 Mar 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-3,566	-100%	$0.000000	0	05 Mar 2025	Ordinary Shares	3,566		Direct	F1, F2, F3
transaction	TEVA	Restricted Share Units	Award	$0	+14,150		$0.000000	14,150	05 Mar 2025	Ordinary Shares	14,150		Direct	F1, F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 3,566 vested on March 5, 2025.
F4	Restricted share units were granted on March 5, 2025, with 3,537 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029.